We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Regulator Gene a Melanoma Target

By Biotechdaily staff writers
Posted on 25 Jul 2005
Cancer researchers have found that the MITF (microphthalmia-associated transcription factor) master regulator gene is highly amplified in malignant melanoma and presents an attractive target for chemotherapy.

Investigators at Yale University (New Haven, CT, USA) used the new HistoRx Incorporated (New Haven, CT, USA) AQUA (Automated Quantitative Analysis) System to analyze gene numbers in cultures of NCI160 melanoma cells. More...
AQUA is a system that combines fluorescence-based imaging with automated microscopy and high-throughput tissue microarray technologies.

The researchers reported in the July 7, 2005, issue of Nature that the melanocyte master regulator MITF was the target of novel melanoma amplification. MITF amplification was more prevalent in metastatic disease and correlated with decreased overall patient survival. Expression of multiple copies of the MITF gene enhanced the ability of the melanoma cells to develop resistance to chemotherapy. Therefore, drugs designed to prevent amplification of the gene would increase sensitivity to anti-cancer drugs.

"According to the study, these data suggest that MITF represents a distinct class of ‘lineage survival' or ‘lineage addiction' oncogenes required for both tissue-specific development and tumor progression,” said contributing author Dr. David Rimm, associate professor of pathology at the Yale School of Medicine.




Related Links:
Yale University
HistoRx Incorporated

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Multi-Chamber Washer-Disinfector
WD 390
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.